semaglutide merck OZEMPIC® (semaglutide) | Inj | Novo Nordisk Novo Nordisk to launch Ozempic

Abstract To exclude an excess risk of cardiovascular (CV) events, CV outcomes trials (CVOTs) have assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), in patients with type 2 diabetes and established CV disease or CV risk factors

Dizziness is classified as an uncommon side effect of Ozempic, occurring in fewer than 1 in 100 but more than 1 in 1,000 patients according to MHRA-approved product information

Youre not just maintaining weightyoure building a life you love, and were honored to be by your side.

As medical research continues to evolve in 2026, these medications are becoming more accessible and versatile, including new oral and weekly options

All told, the project is both resurrection and evolution

A structured rotation plan helps distribute tissue stress evenly across multiple sites